The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer's drug that had provoked fierce criticism of the company and regulators after it was approved based on weak evidence that it would help patients.
The company will also stop a clinical trial that the Food and Drug Administration had ordered to confirm whether the drug is effective in slowing the progression of Alzheimer's disease.
[
add
]
[
|
|
...
]